NCT05724693

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

A Phase 1, Multicenter, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Bemnifosbuvir (AT-527) in Adult Subjects With Normal and Impaired Hepatic Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose

Conditions

• Healthy Volunteer
• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	Bemnifosbuvir (BEM)	Day 1: A single dose of BEM will be administered

Timeline

• Start date: 2023-01-30
• Primary completion: 2024-04-23
• Completion: 2024-04-23
• First posted: 2023-02-13
• Last updated: 2024-07-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study